Member Info for PrivateRyan

If any rto happens lamellar will acquire the shares/ assets for a nominal sum pay down the Hercules loan and then seek funding to develop new applications and trials. That will be at their cost and for their risk. That are not going to pay existing shareholders the future benefits now. Current shareholders may end up with a small holding in the new expanded company and so benefit from future success. Just as we hoped to with motif. But expect massive dilution

Thank you for that in depth analysis and refutation Truthcaller.

Changer! Check my posting history. I was all in .... then they rnsed that they hadn’t managed to find a buyer after several months of comprehensive outreach. Very disappointing but it is what it is.

I was indeed invested The rns was the game banger. When the facts change....

Au contraire You win some you lose some. You have to be dispassionate dear boy

If you knew the history monster you would know that motif bought iclaprim from another company after it had done all the work but failed the fda test. They paid a paltry sum for it despite all the expenditure the predecessor had incurred. We are now in-that position. We couldn’t sell it.

Thank you dear bobby! Suspect it may not be widely popular!

I have been here for years and I indeed made that point about the inherent value of iclaprim and fully expected the proposed sale would occur. Sadly it didn’t. There may be future value if lamellar can use it as currently Hercules hold it as security for 6 m loan. Then llamellar would need funds to do the trials. All possible. But that risk and expenditure will be for llam. No benefit to current shareholders

Because I dislike rampers who pump and dump I prefer the truth even if it is unpalatable

Yes people cashing in their chips. Don’t trust the price to go higher so exercise and get out.

In an rto the private company takes over the cash shell to save the costs of acquiring a listing A few hundred grand. If iclaprim had been sold then the cash would have been larger and therefore Mtfb share price much higher The acquirer would be content to pay that as they would be acquiring cash. That is what I expected to happen. But no sale. So Mtfb is worth peanuts everyone. It’s all fantasy being peddled.

And why 100million for a company with 850k and maybe some aim listing rto savings . Nobody came in to buy iclaprim. It’s not worth anything I am afraid It’s all b s

I looked back at proactive videos. He said in 18 November that a lot of work was being done to acquire the c e mark. So should be soon. Even imminent!

That’s very helpful p m Thanks for taking the time And also the info re the pilot. I recall Tom saying they were doing a lot of work last year maybe around September when there was the bleepa exhibition so hopefully not too Long now.

Pm how long did it take roughly?
Pr!

But did Pando get on the list of top ten UK recommendations to international governments for fighting covid ? You may have been premature Elise ! We will see Cheers

You may be right now I have looked at it though I thought that is what the ex doctor said. Let’s see if you get a response. I sent a tweet -my first ever- but probably went to somebody else given my tech skills !
A photo though was mentioned by the ex doctor . What about mri scans. I still have hope

I saw that too! Only hope is that it uses what’s app and the privacy issue with that has already been flagged. Also he talked about taking a photo but what of? Maybe it is less important to have clinical quality in some circs? I did note he was an ex doctor btw. But who knows if this is real competition. Tom says our product is the only one that meets all the demands. I hope he is right ! And I have a lot of these too so will keep watching closely.

Well that does sound like real positive news. Thanks very much for sharing. I suppose we have to wait for the judge to grant the motion but in the circumstances I presume he has to. Then we claim on IOU’s or the successor You can’t simply take assets out of a business and not take the liabilities or alternatively there would be an inter company debtor left in ioxus ie the transferee. I suppose the company might be busy though in which case we get a share like other unsecured creditors. But as chap said a win is a win. Can only be good news

Maybe one includes transaction costs and the other is clean ? Just a thought